FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
What happened
FDA reviewed Momentum Health’s website, https://momentumhealth360.com, in March 2026 and found it offered compounded semaglutide, tirzepatide, and liraglutide products. FDA said the pictured labels name Momentum Health as the compounder even though it is not, and the site claimed the products have the “same active ingredient” as Mounjaro, Zepbound, Wegovy, or Ozempic and came from an “FDA-licensed compounding facility.” FDA called these representations false or misleading and said they misbrand the products.
What FDA found
The website labels name Momentum Health as the compounder even though it is not the manufacturer.
21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]The website says the compounded drugs have the “same active ingredient” as Mounjaro, Zepbound, Wegovy, or Ozempic, which implies FDA approval or evaluation they do not have.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]The website says the products come from an “FDA-licensed compounding facility,” but FDA does not license or approve compounding facilities or their compounded drugs.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA says selling these misbranded drugs in interstate commerce is prohibited.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells Momentum Health to respond within 15 business days to the Office of Compounding Quality and Compliance with corrective actions. It asks the company to identify who produces the compounded drugs, provide sample labeling, and address or remove the misleading website claims.
Who should pay attention
- telehealth platforms selling compounded GLP-1 drugs
- compounding pharmacies and outsourcing facilities whose products are promoted online
- marketing and compliance teams for compounded drug websites
This is a summary. Read the original letter on fda.gov.